Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.64 |
| ▸ | NOS1 | P29475 | 2/20 | 0.64 |
| ▸ | NOS2 | P35228 | 2/20 | 0.64 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.31 |
| ▸ | GNPAT | O15228 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7367475 | 1.00 | NOS3 (0.64) | NOS3NOS1NOS2FOLH1GNPAT | |
| SCHEMBL288209 | 0.84 | NOS3 (0.47) | NOS3NOS1NOS2 | |
| SCHEMBL26399370 | 0.81 | NOS3 (0.40) | NOS3NOS1NOS2FOLH1GNPAT | |
| SCHEMBL31754339 | 0.81 | NOS3 (0.40) | NOS3NOS1NOS2FOLH1GNPAT | |
| Arginine SCHEMBL16398116 | 0.80 | NOS2 (0.57) | NOS3NOS1NOS2 | |
| SCHEMBL8709503 | 0.78 | NOS2 (1.00) | NOS3NOS1NOS2 | |
| SCHEMBL2307076 | 0.78 | NOS2 (1.00) | NOS3NOS1NOS2 | |
| SCHEMBL25358064 | 0.77 | FOLH1 (0.38) | NOS3NOS1NOS2FOLH1GNPAT | |
| SCHEMBL25358066 | 0.77 | FOLH1 (0.38) | NOS3NOS1NOS2FOLH1GNPAT | |
| Acetic Acid SCHEMBL23160943 | 0.75 | NOS2 (0.93) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298747-A1 | Methods and Compositions For Treatment of Nitric Oxide-Induced Clinical Conditions | BIO HOLDING, INC. (US) | 2009-12-03 | — | — | US | claimed |
| US-20040220242-A1 | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | claimed |
| US-20040220113-A1 | Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | claimed |
| WO-1998049199-A1 | CARDIOVASCULAR DISEASE RISK ASSESSMENT | PANORAMA RESEARCH, INC. (US) | 1998-11-05 | — | — | WO | claimed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-11313866-B2 | Method of diagnosing and treating asphyxia | INFANDX AG (DE) | 2022-04-26 | — | — | US | disclosed |
| EP-2249161-B1 | Method of diagnosing asphyxia | INFANDX AG (DE) | 2020-05-13 | — | — | EP | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20180011111-A1 | Method of Diagnosing and Treating Asphyxia | INFANDX AG (DE) | 2018-01-11 | — | — | US | disclosed |
| US-9791459-B2 | Method of diagnosing and treating asphyxia | INFANDX AG (DE) | 2017-10-17 | — | — | US | disclosed |
| EP-2427773-B1 | METHOD OF DIAGNOSING ASPHYXIA | INFANDX AG (DE) | 2016-07-06 | — | — | EP | disclosed |
| EP-2449488-B1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES LIFE SCIENCES AG (AT) | 2015-01-14 | — | — | EP | disclosed |
| US-6743614-B1 | FOR DRUG SCREENING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-06-01 | — | — | US | disclosed |
| US-6489308-B1 | ONE AGENT EXHIBITING MAMMALIAN ALPHA 1-ANTITRYPSIN OR ALPHA 1-ANTITRYPSIN-LIKE ACTIVITY, AND A FREE RADICAL SCAVENGER SUCH AS 2,6,8-TRIHYDROXYPURINE, DIHYDRORHODAMINE, OR A COMBINATION THEREOF | TRUSTEES OF UNIVERSITY OF TECHNOLOGY CORPORATION | 2002-12-03 | — | — | US | disclosed |
| US-5721210-A | OLIGOPEPTIDES AS ANTIINFLAMMATORY AGENTS OR INTEGRIN RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 1998-02-24 | — | — | US | disclosed |
| EP-0677060-A1 | PEPTIDE INHIBITORS OF CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1995-10-18 | — | — | EP | disclosed |
| WO-1994015958-A2 | PEPTIDE INHIBITORS OF CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1994-07-21 | — | — | WO | disclosed |
| EP-0538399-A4 | — | — | 1994-05-04 | — | — | EP | disclosed |
| EP-0538399-A1 | CYCLIC CELL ADHESION MODULATION COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992000995-A1 | CYCLIC CELL ADHESION MODULATION COMPOUNDS | TANABE SEIYAKU CO. LTD. (JP) | 1992-01-23 | — | — | WO | disclosed |